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Catecholaminergic neurons control diverse cognitive, motor, and en-
docrine functions and are associated with multiple psychiatric and
neurodegenerative disorders. We present global gene-expression
profiles that define the four major classes of dopaminergic (DA)
and noradrenergic neurons in the brain. Hypothalamic DA neurons
and noradrenergic neurons in the locus coeruleus display distinct
group-specific signatures of transporters, channels, transcription,
plasticity, axon-guidance, and survival factors. In contrast, the
transcriptomes of midbrain DA neurons of the substantia nigra and
the ventral tegmental area are closely related with <1% of dif-
ferentially expressed genes. Transcripts implicated in neural plas-
ticity and survival are enriched in ventral tegmental area neurons,
consistent with their role in schizophrenia and addiction and their
decreased vulnerability in Parkinson’s disease. The molecular pro-
files presented provide a basis for understanding the common and
population-specific properties of catecholaminergic neurons and
will facilitate the development of selective drugs.
Catecholaminergic (CA) neurons producing the neurotrans-mitters dopamine (DA) and noradrenalin (NA) are orga-
nized in anatomically discrete groups and constitute 1 of 107
cells in the vertebrate CNS (1, 2). The most prominent groups
of DA neurons reside in the substantia nigra (SN; A9 cell group;
10,000 neurons in the rat) and the ventral tegmental area
(VTA; A10; 25,000 neurons) of the midbrain. The SN neurons
provide the nigrostriatal ascending inputs to the telencephalon
and comprise a key component of the extrapyramidal motor
system controlling postural reflexes and initiation of movement.
DA neurons in the adjacent VTA give rise to mesocortical and
mesolimbic pathways that are implicated in control of emotional
balance, reward-associated behavior, attention, and memory.
Additional groups of DA neurons reside in the medial zona
incerta of the hypothalamus (A13; 900 neurons) and partici-
pate in the regulation of endocrine functions. The largest
collection of NA neurons resides in the pontine locus coeruleus
(LC; 1,500 neurons). These neurons form a modulatory pro-
jection system to most CNS areas and contribute to the regula-
tion of emotional status, sensory perception, arousal, sleep–
wake patterns, and most autonomic functions.
Consistent with their varied functions, the CA neurons are
associated with multiple neurodegenerative, psychiatric, and
endocrine disorders. Selective degeneration of DA neurons in
the SN but not in the VTA or the hypothalamus leads to
Parkinson’s disease (PD) (3–7), whereas abnormal function of
the VTA DA neurons has been linked to schizophrenia, atten-
tion deficit, addiction, and hyperactivity disorders (8–11). In
addition, dysfunction of hypothalamic DA neurons can cause
hyperprolactinemia, an endocrine disorder of the reproductive
system (12), whereas changes in the activity of the NA system
have been linked to depression as well as sleep disorders (13, 14).
The drugs currently available for therapy reflect the critical
role of CA systems in disease states. Compounds substituting for
the diminished levels of DA in SN neurons are palliative for PD
(15–17), whereas drugs blocking the function of VTA neurons
are the mainstay therapy for schizophrenia (18). DA drugs are
also used to control hyperprolactinemia, whereas antidepressant
drugs (13) and also drugs of abuse, such as amphetamines and
cocaine, act on transporter systems of CA neurons (8, 9).
Because these drugs do not distinguish between classes of CA
neurons, the desired effects in one condition become the adverse
effects in another disease. For example, PD-like extrapyramidal
motor disturbances are common in schizophrenia drug therapy,
whereas hallucinations and paranoia are common side effects of
DA drug therapy for PD and hyperprolactinemia. Here, we
report the genome-wide expression profiles of four major sub-
populations of adult CA neurons. This study provides a foun-
dation for mechanistic understanding of the development, ste-
reotypic positions, control of innervation targets, function, and
disease vulnerability of these neuronal classes and for the
identification of selective drug targets.
Materials and Methods
Tissue Preparation and Immunohistochemistry. Adult (7- to
9-month-old) female Sprague–Dawley rats were anesthetized
and killed by decapitation. The brains were rapidly dissected and
immediately frozen on dry ice. We mounted 12-m cryosections
on polyethylene-naphthalene membrane slides pretreated with
0.1% poly-L-lysine for 5 min, followed by 30 min of UV
irradiation. The sections were fixed immediately in 100% ethanol
for 30 s, followed by acetone for 3 s, and air-dried. After
rehydration in PBS (pH 7.0) for 5 s, the sections were stained for
2 min in PBS (pH 7.0) containing 100 gml anti-tyrosine
hydroxylase (TH) Ab (clone TH-16; Sigma) that had been
labeled with the Alexa Fluor 488 mAb-labeling kit (Molecular
Probes) according to the manufacturer’s instructions. Rehydra-
tion and staining were performed in the presence of 1 unitl
RNase inhibitor (Roche). The sections were washed twice in
PBS for 5 s; dehydrated for 30 s in 75%, 95%, and 100% ethanol,
respectively; and air-dried at room temperature.
Laser Microdissection, RNA Isolation, and Amplification. Single neu-
rons were isolated from immunostained cryosections by using a
PALM Robot–Microbeam system (PALM Microlaser Technol-
ogy, Bernried, Germany). To facilitate detection of fluorescent
neurons, a drop of 100% ethanol was applied to the section
during cell selection. The sections were allowed to air dry, and
neurons were dissected and catapulted into 30 l of lysis buffer.
Total RNA from 200 pooled neurons was isolated by using the
PicoPure kit (Arcturus, Mountain View, CA), and contaminat-
ing genomic DNA was removed during the isolation by an
on-column DNase digestion step. The common reference RNA
was generated from three whole brains of age-matched female
rats. RNA was isolated by using RNA-Bee (Tel-Test, Friends-
wood, TX), followed by DNase digestion with the DNAfree kit
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(Ambion, Austin, TX). The RNA from dissected neurons and a
common reference was amplified by two rounds of T7-based
linear amplification (19) using the RiboAmp kit (Arcturus) with
the following modifications: to minimize generation of template-
independent amplification product from the T7 primer, a 1:5
dilution of primer A was used for the first round of cDNA
synthesis, and the reaction volume was scaled down by 50%. The
yield and size distribution of the amplified RNA product were
evaluated by microfluidic gel electrophoresis with a bioanalyzer
(Agilent, Palo Alto, CA).
RNA Labeling, Microarray Hybridization, and Data Analysis. Detailed
protocols for probe synthesis and DNA microarray hybridization
are available at http:cmgm.stanford.edupbrownprotocols
index.html. In short, 2 g of amplified RNA was random primed to
generate single-stranded aminoallyl-dUTP cDNA targets, which
were subsequently coupled with either Cy3 (whole-brain reference)
or Cy5 (experimental sample). Images were analyzed by using
AGILENT FEATURE EXTRACTION software (version A.6.1.1). Pro-
cessing included local background subtraction and a rank consis-
tency-based probe selection for LOWESS normalization. The data
were filtered with respect to signal significance. A two-tailed t test
was used to determine significance of the signal versus background,
and spots with a P value of 0.01 in the red or green channel
were omitted. Data were log2-transformed and analyzed by using
CLUSTER and TREEVIEW (20). Statistical analysis was performed by
using various functions of the significance analysis of microarrays
algorithm SAM (21), with a false-discovery rate set at 1%. Only
genes for which information was available for 80% of arrays were
included in the analysis. Four independent experiments were
conducted for every cell type, and in each experiment, cells
were isolated from different animals and RNA extraction, ampli-
fication, labeling, and hybridization were carried out separately.
The mean correlation coefficient of the expression ratios (log2-
isolated neuronswhole brain) between replicates was 0.86, and
values ranged from 0.81 to 0.93.
In Situ Hybridization. Probes were amplified from rat brain RNA by
nested RT-PCR with T3 promoter sequences attached to the 5 end
of the 3 nested primers. The sequence-confirmed PCR products
were used as templates for synthesis of digoxigenin-labeled RNA
probes. Coronal cryosections (20 m) of adult rat brains were
air-dried for 30 min and fixed in 4% paraformaldehyde for 15 min.
The sections were bleached in 6% H2O2 for 10 min, digested with
1 gml proteinase K in PBS for 5 min, and refixed in 4%
paraformaldehyde, followed by a 10-min acetylation step in 0.25%
acetic anhydride100 mM Tris, pH 7.5, and two washes in 2 SSC
(1 SSC  0.15 M sodium chloride0.015 M sodium citrate, pH 5).
The sections were prehybridized in hybridization buffer [5 SSC,
pH 51% blocking reagent (Roche)50% formamide5 mM
EDTA0.1% Tween 2010% dextrane sulfate100 g/ml salmon
sperm DNA100 g/ml tRNA100 g/ml heparin] for 1 h at 65°C
and hybridized for 20 h at 65°C in 100 l of hybridization buffer
containing 1 gml digoxigenin-labeled probe. The slides were
washed at 60°C two times for 10 min in 5 SSC50% formamide,
two times for 15 min in 1 SSC, and for 30 min in 0.2 SSC,
followed by digestion with 10 gl RNase for 15 min at 37°C.
Digoxigenin epitopes were detected with alkaline phosphatase-
coupled antidigoxigenin Fab fragments (Roche) and developed
with BM purple (Roche) for 24–48 h.
Results
Profiling Individual Classes of CA Neurons. We have determined the
gene-expression profiles of DA neurons in the SN, VTA, and
dorsal hypothalamus, and of NA neurons in the LC of normal
adult rats. The neurons were identified in cryosections of the
respective brain regions by a rapid one-step immunostaining of
TH, which is the rate-limiting enzyme for DA and NA biosyn-
thesis (Fig. 1A). From each class, 200 neurons were isolated by
laser microdissection (Fig. 1B), and the RNA integrity of the
tissue section was confirmed by quantification of the 18S and 28S
ribosomal RNAs (Fig. 1C). The RNA of microdissected neurons
was subjected to two rounds of T7-based linear amplification and
labeling (19) and was hybridized to 14,800 element rat cDNA
microarrays. A common reference was generated by pooling and
amplifying RNA from three whole brains of age-matched rats
and used for competitive hybridization.
To assess the validity of our approach, we first focused on the
expression patterns of known key enzymes involved in DA and NA
biosynthesis and vesicular transport (Fig. 2). TH was the most highly
enriched transcript in all three examined DA cell groups (150-fold
compared with the whole-brain reference) and the second most
highly enriched in the NA neurons. In contrast, DA--hydroxylase
(DBH), which catalyzes the conversion of DA to NA, was exclu-
sively enriched in LC neurons (500-fold over reference). Addi-
tional genes that were expressed at high levels in all CA populations
included the CA-synthesis enzymes aromatic amino acid decarbox-
ylase, GTP cyclohydrolase I, and pterin-4--carbinolamine dehy-
dratase, and the vesicular monoamine transporter 2, which medi-
ates the transport of monoamine neurotransmitters into synaptic
vesicles. As expected, the ubiquitously expressed dihydropteridine
reductase did not show significant enrichment in any of the cell
populations.
Fig. 1. Isolation of intact RNA from CA neurons. (A) Identification of CA
neurons in the SN, VTA, zona incerta, and LC in coronal brain sections of the
rat by rapid TH immunostaining. (B) Laser microdissection of individual neu-
rons in the SN. (C) Preserved integrity of RNA in immunostained brain sections.
Scale bar indicates 250 m (A Upper and Lower Right), 75 m (A Lower Left),
and 15 m (B).
Fig. 2. Expression of CA biosynthetic enzymes and transporters in DA and NA
cell groups. The ratios of expression in the respective cell group compared with
the whole-brain reference are shown. Error bars indicate 95% confidence
interval. AADC, aromatic amino acid decarboxylase; DHPR, dihydropteridine
reductase; GTPCH I, GTP cyclohydrolase I; PCD, pterin-4--carbinolamine de-
hydratase; VMAT-2, vesicular monoamine transporter 2.
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Lineage Relationships Between CA Neuron Subclasses. Having vali-
dated our approach with known genes, we next sought to establish
the lineage relationships between the different classes of CA
neurons as revealed by overlapping and distinct patterns of gene
expression. To this end, we used unsupervised hierarchical cluster-
ing (20) to group the four CA cell classes based on all of the genes
represented on the array. Independent biological replicates repre-
senting a given cell group clustered together, indicating the exis-
tence of specific transcriptomes in each subgroup of CA neurons.
The phylogenetic relationship between the individual cell classes is
shown in a dendrogram (Fig. 3A). The SN and VTA DA neurons
displayed highly similar signatures of gene expression, suggesting
that these anatomically adjacent cell groups are closely related at
the molecular level. In contrast, the profile of incertohypothalamic
DA neurons was related only distantly to those of the SN and VTA
neurons, despite the fact that all three groups of neurons use the
same transmitter. In fact, hypothalamic A13 DA neurons are not
positioned markedly closer to midbrain DA neurons in the phylo-
genetic tree than the NA neurons are.
To illustrate shared and cell type-specific gene expression in
the CA system, we selected transcripts with at least 4-fold higher
expression compared with whole brain in any one of the four cell
groups and organized them in a Venn diagram (Fig. 3B). NA
neurons in the LC expressed the highest number of enriched
transcripts (412), followed by SN (279), VTA (264), and hypo-
thalamic DA (170) neurons. As expected from the phylogenetic
tree, there was a large overlap between SN and VTA (46%;
171372). In contrast, SN and A13 neurons shared 18% (68
381), SN and LC shared 22% (126565), and A13 and LC shared
17% (85497) of their enriched transcripts. Only 44 transcripts
were enriched in all four examined CA groups.
In an alternative approach to assess the molecular phylogeny,
we determined the percentage of transcripts with differences
between any two given cell groups by significance analysis (21).
SN and VTA differed in only 122 (1%) of their expressed
genes. In contrast, there were 766 (5%) differentially ex-
pressed transcripts between SN and A13, 1,079 (7%) differ-
entially expressed transcripts between SN and LC, and 1,453
(10%) differentially expressed transcripts between LC and
A13 neurons. Together, these findings demonstrate that each
group of CA neurons displays a unique set of expressed genes,
and they support the hypothesis that SN and VTA neurons are
closely related by lineage andor function.
Transcripts Enriched in All CA Neurons. To identify transcripts that
define CA cell identity irrespective of subclass, we examined the
genes that are enriched in all groups of CA neurons (see Table 1,
which is published as supporting information on the PNAS web
site). The most prominent class included transcripts that are known
to be involved in neurotransmitter synthesis and transport, such as
TH, aromatic amino acid decarboxylase, GTP cyclohydrolase I,
pterin-4--carbinolamine dehydratase, and vesicular monoamine
transporter 2. In addition, we identified genes coding for proteins
that counteract stress-induced cell damage (glutathione peroxidase,
ARC, and ORP150), inflammation-related genes (DAF and MHC
class I heavy chain), genes involved in neural-cell adhesion (neural
cell adhesion molecule and polysialyltransferase 1), and modulators
of DA-receptor activity (calcyon and chloride intracellular channel
3). Of these pan-CA transcripts, 38% were ESTs or coding for
hypothetical proteins, indicating that a large portion of the tran-
scriptome of CA neurons is still uncharacterized.
All CA neurons were found to express aldehyde dehydroge-
nase enzymes; however, they expressed different members of this
protein family (Fig. 4). ALDH1A3 was expressed in the hypo-
thalamus, whereas ALDH1A1 was expressed in the SNVTA.
Both enzymes can convert retinaldehyde to retinoic acid. Sig-
naling of retinoic acid was shown to be involved in many
developmental processes, including the specification of motor-
neuron subclasses (22). LC neurons express ALDH3A1, which
is not capable of synthesizing retinoic acid but may be involved
in neurotransmitter metabolism and detoxification.
A Common Signature of Midbrain DA Neurons. Having identified a
pan-CA signature, we further sought to identify genes that are
differentially expressed in subsets of CA neurons. Gene filtering
and multiclass significance analysis (21) revealed a set of 534
genes that differ in expression between at least two groups of CA
neurons. Genes and experimental samples were grouped by
supervised two-dimensional hierarchical clustering (Fig. 4A).
This analysis again demonstrated the high degree of similarity
between SN and VTA DA neurons, as well as the distant
relationship of the SNVTA with both A13 DA and LC neurons.
The cluster of genes with enriched expression in SN and VTA
neurons contained a large number of transcriptional regulators
(ZFH-4, ATBF1, PBX1, FOXP2, IFI-16, and SATB1) and regu-
lators of synaptic signaling andor plasticity [the calcineurin inhib-
itor ZAKI-4, synaptotagmin I, the kinesin-related protein Hash, the
calcium-activated protein for secretion, and the glutamate receptor-
interacting protein 2, which is involved in the synaptic targeting of
(-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, AMPA)
receptors]. Three apoptosis-related transcripts, caspase 7, SM-20,
and PERP (p53-effector related to pmp-22), were also highly
enriched in the midbrain DA cluster. SM-20 is a mitochondrial
protein that promotes caspase-dependent cell death in neurons,
whereas PERP is a positive effector of p53-induced neuronal
apoptosis. Aldehyde dehydrogenase 1, which is known to be highly
and specifically expressed in the SN and VTA, served as a validating
marker for this gene cluster.
A Complex NA Signature in the LC. As expected from the Venn
diagram, the LC cluster contained the largest collection of cell
group-specific transcripts (Fig. 4A). Marker genes for this cluster
included DBH, monoamine oxidase A, and cytochrome b561,
which is a major transmembrane protein of CA secretory vesicles
that provides reducing equivalents for the DBH reaction. AP-2,
a member of the AP-2 family of retinoic acid-induced transcrip-
tion factors was highly enriched in LC neurons. The closely
related transcription factor AP-2, which recognizes the same
target sequence and shares a highly conserved DNA-binding and
dimerization domain with AP-2, has been shown to activate the
expression of TH and DBH (23) and to be essential for the
development of NA LC neurons in zebrafish (24). We also
observed high specific expression of potential vulnerability fac-
tors, the Cu transporter 1, the -glutamyltranspeptidase-related
Fig. 3. Relationship among classes of CA neurons. (A) Dendrogram showing
the relationship of the gene-expression profiles of all experiments. The tree
was generated by unsupervised hierarchical clustering based on all features
that were significant (P  0.01) and 2.6 SDs over background in 80% of all
experiments (13,173 of 14,797 genes). (B) Venn diagram showing shared and
distinct expression of genes enriched in CA neurons. Genes with 4-fold
expression compared with the whole-brain reference were selected for each
group of neurons, with a false-discovery rate of 1%.












enzyme, and prostaglandin E synthase. Cu is an essential cofac-
tor for various enzymes including CuZn superoxide dismutase,
cytochrome oxidase, and DBH. However, excess of Cu combined
with glutathione metabolites leads to free-radical damage and
possible neuronal dysfunction (25). LC neurons also expressed
factors known to protect from oxidative damage andor apo-
ptosis-like pigment epithelium-derived factor, neuroglobin as
well as IAP and TRAF, which can both mediate antiapoptotic
TNF signaling.
Transcripts Defining Hypothalamic A13 DA Neurons. The A13 DA
neurons were characterized by high and specific expression of
multiple transcriptional regulators (Hnf-6, Lmo2, Bteb2 Isl-1,
Nkx2.1, Dlx, Six3, Lim1, and Prox1 Arx; Fig. 4A). Six3 has been
shown to alter the regional responses to Fgf8 and Shh, which is
required for development of the hypothalamus (26). The Arx, Dlx,
Isl-1, Lim1, and Nkx2.1 are important regulators of proliferation,
migration, and differentiation of neurons in the embryonic fore-
brain (27). In Dlx12 mutants, for example, the A13 DA neurons
do not form (28). The functions of Hnf-6, Lmo2, Bteb2, and Prox1
in the A13 DA neurons are currently not known. The fact that
expression of multiple developmental regulators is sustained sug-
gests additional functions of these genes in the adult brain.
Differential Gene Expression in SN and VTA Neurons. Even though SN
and VTA neurons are located in close proximity, develop in
response to the same inductive signals, and have partially overlap-
ping axonal projection domains, they mature to innervate distinct
targets, control different brain functions, and display different
vulnerabilities to neurodegeneration. We identified 122 genes with
differential expression between SN and VTA neurons by two-class
significance analysis (Fig. 4B). Among these factors were transcripts
from various categories, including transcriptional regulators (Sox-6,
Zfp 288, HTF, and NGFI-A), molecules involved in vesicle traf-
ficking [DOC2B, rab3B, and MARCKS (myristoylated alanine-rich
C kinase substrate)], axon guidance (neuropilin 1, slit-2, and ephrin
Fig. 4. Supervised cluster analysis of genes with differential expression between CA cell groups. (A) Genes were filtered based on their expression level relative
to the whole-brain reference (4-fold higher or lower in at least 3 of 16 experiments), and transcripts with significant differences in expression between at least
two cell groups were selected by multiclass SAM, with a false-discovery rate of 1%. The resulting set of 534 genes and the experimental samples were grouped
based on their similarities of gene expression by two-dimensional hierarchical clustering (Pearson correlation, average linkage). Selected gene clusters with
preferential expression in SNVTA, LC, or A13 cell groups are shown, and known annotated genes are listed. The complete list of genes is provided in Table 2,
which is published as supporting information on the PNAS web site. (B) Differential gene expression between SN and VTA neurons. Genes with significant
differences in expression were identified by SAM (false-discovery rate of 1%) and sorted by hierarchical clustering. Selected genes are annotated. The complete
list of genes is provided in Table 3, which is published as supporting information on the PNAS web site.
13894  www.pnas.orgcgidoi10.1073pnas.0405340101 Grimm et al.
B3), ion channels [CLIC5 (chloride intracellular channel 5), VR1
(vanilloid receptor 1), and NMDAR2C], transporters (VGLUT2
and CNT2), and G protein-coupled receptors (-1B-adrenergic
receptor and GPRC5C).
The two most prominent functional classes encoded factors
involved in synaptic plasticity and in cell survival and protection.
Strikingly, most of these transcripts were expressed at a higher level
in the VTA neurons. The factors with a reported or anticipated
function in synaptic plasticity included the synaptic-adhesion mol-
ecules synCAM and syndecan 2 (29) and the actin-associated
synaptopodin 2, which is required for the formation of the dendritic-
spine apparatus (30). The MARCKS and G substrate have been
implicated in learning and long-term potentiation. Likewise, we
found elevated expression of PLC2 (phospholipase-C-2), an
isoform of PLC1 (phospholipase-C-1), which is thought to be
involved in the maintenance of long-term potentiation (31) and
NGFI-A, an immediate-early gene that is associated with learning
and plasticity. Finally, we have identified the serine proteases
RNK-Met 1 and DISP, as well as the serine protease inhibitor Hai2,
which might contribute to synaptic plasticity by modulation of the
extracellular environment.
VTA-enriched transcripts associated with neuroprotective func-
tions included the neuropeptides PACAP (pituitary adenylate
cyclase-activating peptide) and ANP (atrial natriuretic peptide), the
growth factor BMP-2 (bone morphogenetic protein 2), and
PARM-1 (prostatic androgen-repressed message 1). PACAP and
BMP-2 are known survival factors for ventral mesencephalic DA
neurons that can protect from 6-hydroxydopamine and MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (32–34). ANP can
counteract oxidative stress and excess NO (35, 36), whereas
PARM-1 is implicated in suppression of apoptosis (37). The
BMP-inducible antagonists follistatin and chordin were also selec-
tively expressed in the VTA, which indicates active BMP-signaling
controlled by autoregulatory feedback loops. Enriched expression
in VTA over SN neurons was also observed for enzymes with
detoxifying properties: extracellular superoxide dismutase, an an-
tioxidant enzyme that attenuates brain and lung injury from
oxidative stress (38); lipoprotein lipase, a key enzyme involved in
the metabolism of lipoproteins, which protects from cell death
induced by oxidized lipoproteins (39); and UDP-glucuronosyltrans-
ferase, which detoxifies compounds by conjugation to glucuronic
acid. However, expression of PKC-, which has been shown to
mediate DA cell apoptosis induced by MPTP or pesticides was
significantly lower in VTA neurons compared with the SN (40, 41).
Two additional genes that could play an important role in the
pathobiology of PD were -synuclein and the zinc transporter ZIP4.
Interestingly, -synuclein transcripts are highly enriched in both SN
and LC (28- and 29-fold, respectively), which are vulnerable to PD
and is dramatically lower in the less vulnerable VTA (4-fold) and
A13 (2-fold) neurons. ZIP4 is a member of the Zn2 uptake
transporter family that has not been described in brain tissues
before. We detected highly specific expression of the ZIP4 mes-
senger in the neurons of the VTA (250-fold) and the SN
(100-fold).
Validation of Cell Group-Specific Gene Expression. To independently
validate the microarray-derived molecular signatures of the CA
neurons we have analyzed the distribution of 14 transcripts by in
situ hybridization (Fig. 5). We found a tight correlation between
the expression patterns that were predicted by microarray and
the expression patterns determined by in situ hybridization for
nine transcripts, whereas in five cases, we were unable to detect
signal in situ, possibly because of low mRNA abundance. Con-
sistent with the microarray analysis, the in situ hybridization
revealed expression of the MHC class I heavy chain and the
hypothetical protein LOC313453 in all four CA populations. In
contrast, expression of the transcription factor HNF-6 was
confined to the hypothalamic A13 cell group, whereas the Cu
transporter Ctr1 and the hypothetical protein LOC290558 were
restricted to the LC. Likewise, the zinc transporter ZIP4 was
highly expressed in the VTA and SN. The -synuclein transcripts
were abundant in SN and LC and the PARM-1 message was
enriched in the VTA and A13 cell groups. Together, these
findings confirm the authenticity of the microarray analysis.
Discussion
In this study, we have analyzed the molecular signatures that
define the four major subpopulations of CA neurons. We have
shown that individual neurons can be identified, isolated from
brain tissue, and subjected to microarray analysis. Phylogenetic
examination revealed that, despite considerable heterogeneity
between the SN and VTA DA system with respect to cell
morphology, target innervation, electrophysiological properties,
and disease susceptibility, these two neuronal cell types differ by
1% of their transcripts. In contrast, 5% of the transcripts in the
hypothalamic DA neurons differed from those of the SN or VTA
neurons. DA neurons in the midbrain and hypothalamus each
expressed specific sets of transcriptional regulators, suggesting
that although both neuronal classes depend on Fgf8 and Shh for
their early specification (42), their later phenotype is main-
tained, in part, by independent regulatory cascades. Such a
cascade would include the DA midbrain- and forebrain-specific
transcription factors PBX1, ZFH-4, IFI 116, Bteb2, Lmo2,
Prox1, and Hnf-6 that have been identified here, as well as the
known transcriptional regulators of DA differentiation and
survival Nurr1, Lmx1b, and Pitx3.
The complexity of a given gene profile seems to be correlated
with diversity of projections and complexity of biological func-
Fig. 5. Validation of the gene-expression profiles by in situ hybridization. As predicted by microarray analysis, MHC class I heavy chain and the hypothetical
protein LOC313453 were detected in all four cell groups, whereas expression of HNF-6 was restricted to the hypothalamus, and Ctr1 and the hypothetical protein
LOC290558 were restricted to the LC. ZIP4 expression was strong in SN and VTA, whereas -synuclein transcripts were abundant in the SN and LC but low in the
VTA and A13 cell groups. The PARM-1 message was abundant in the VTA and A13 cell groups, with lower levels in the SN and LC. Expression of PARM-1 was not
confined to CA cell groups, as expected from the low ratios of expression measured by microarray.












tions. The LC NA system, which innervates much of the CNS and
regulates emotional, cognitive, and sleep–wake functions, ex-
pressed the highest number of specific genes. In contrast,
hypothalamic A13 neurons, which have simpler projections and
control mainly endocrine functions, displayed the lowest tran-
script complexity.
Despite the high similarity of the transcriptomes in SN and
VTA neurons, we were able to identify a number of subpopu-
lation-specific genes. Among the gene transcripts enriched in the
VTA, several encoded proteins that are implicated in synaptic
plasticity. These factors may contribute to the long-term synaptic
plasticity elicited by psychostimulants, leading to drug addiction
(43). A critical role of PLC1 in the regulation of long-term
adaptations to drugs has recently been demonstrated by over-
expression experiments in the VTA (44). Likewise, the expres-
sion of the learning- and plasticity-associated immediate-early
gene Zif268 is induced in VTA neurons upon drug-conditioned
stimulation and decreases during prolonged withdrawal (45, 46).
VTA neurons were also enriched for several factors that are
involved in axonal pathfinding and neuronal migration (neuro-
pilin-1, slit-2, and ephrin B3). During development, SN neurons
target mainly the dorsolateral striatum, whereas VTA neurons
mainly innervate the ventromedial striatum. The molecular
signals that regulate the development of these pathways have
been characterized only partially (47). The differential expres-
sion of multiple members of the ephrinEph and slitrobo
families identified here could have important functions in the
maintenance and stability of neuronal networks, in adult plas-
ticity and remodeling, and possibly in schizophrenia, a disease
that is most likely linked to abnormal development of cortical
areas innervated by VTA neurons (48).
One of our goals was to identify genes that may influence the
selective vulnerability of CA neurons in PD. The SN is most
susceptible to PD pathology, whereas the adjacent VTA DA
neurons are less vulnerable and hypothalamic DA neurons are
spared (3–6, 49). The same selective vulnerability of DA neuron
subpopulations has been observed in rodent and primate models
of PD (7, 50–52). The sparing of VTA neurons could be
mediated by selective expression of neuroprotective factors,
including neurotrophic factors (BMP-2, PACAP, and ANP),
detoxifying enzymes (EC-SOD, lipoprotein lipase, and UDP-
glucuronosyltransferase), the antiapoptotic factor PARM-1, and
decreased levels of the proapoptotic PKC-. We also observed
selective high expression of -synuclein in neurons of the SN and
in LC NA that degenerate in PD, which may modify the toxic
effects of the widely expressed -synuclein protein. Likewise,
selective expression of the Zn2 transporter by the SN and VTA
may play a role in the pathophysiology of PD. Low concentra-
tions of Zn2 can exert a cell-protective effect; however, excess
of Zn2 is neurotoxic and has been shown to promote degen-
eration of midbrain DA neurons (53).
In summary, the molecular signatures of the major classes of
CA neurons can advance our understanding of the characteristic
features and functions of these neurons and facilitate the dis-
covery of subgroup-selective drug targets.
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